Lumos Diagnostics Holdings Limited (ASX: LDX) has opened a Share Purchase Plan (SPP) offering eligible shareholders the chance to invest up to A$30,000 at A$0.225 per share, accompanied by free options. The SPP aims to raise up to A$2 million and closes on 24 April 2026.
- SPP offers shares at A$0.225 with one free option per two shares
- Eligible shareholders in Australia and New Zealand can apply up to A$30,000
- Target raise of A$2 million with potential for oversubscriptions
- SPP closes on 24 April 2026, results announced 1 May 2026
- Board reserves right to scale back applications
Details of the Share Purchase Plan
Lumos Diagnostics Holdings Limited (ASX:LDX) has announced a Share Purchase Plan (SPP) allowing eligible shareholders to purchase shares at an issue price of A$0.225 each. For every two shares subscribed, shareholders will receive one free-attaching unquoted option exercisable at A$0.34, expiring on 31 December 2027. The offer is open to shareholders registered as at 7:00pm AEDT on 26 March 2026 with addresses in Australia or New Zealand, excluding US persons and those acting for US accounts.
Eligible shareholders can apply for parcels ranging from A$2,500 up to a maximum of A$30,000. The company has set a target to raise up to A$2 million through the SPP, which equates to approximately 8.9 million shares and 4.4 million options, though it reserves the right to accept oversubscriptions or scale back applications at its discretion.
Application Process and Key Dates
Applications can be made via BPAY® for Australian shareholders or through an alternative electronic funds transfer for New Zealand shareholders who cannot use BPAY®. The SPP opened on 10 April 2026 and is scheduled to close at 5:00pm AEST on 24 April 2026. The results of the SPP and the issue of securities are expected to be announced on 1 May 2026. Shareholders are encouraged to read the full Prospectus and the Target Market Determination for the new options, available on the company’s website.
Context Within Lumos Diagnostics’ Recent Developments
This capital raising initiative follows a period of commercial progress for Lumos Diagnostics, including a recently secured three-year manufacturing contract for its Mold Analyzer system with Micro-Pak. This agreement, which includes an initial US$250,000 purchase order, marks a transition to commercial-scale manufacturing and supports the company’s services revenue stream. The contract was announced just days before the SPP offer, highlighting ongoing operational momentum for the company.
Additionally, Lumos Diagnostics has expanded its US market presence following FDA clearance and a CLIA waiver for its FebriDx® test, which has led to milestone payments and a significant increase in addressable market size. These developments underpin the company’s growth strategy and may influence shareholder interest in the SPP.
Investors should note that the final amount raised will depend on shareholder participation and any scale back decisions by the board. The company has reserved the right to adjust the closing date or other terms subject to regulatory requirements.
Bottom Line?
The SPP offers shareholders a structured opportunity to increase their stake with added options, but the final capital raised will depend on participation and potential scale back decisions.
Questions in the middle?
- How will shareholder participation levels influence the final amount raised under the SPP?
- What impact might the SPP have on Lumos Diagnostics’ share price and capital structure?
- How will proceeds from the SPP be allocated in light of recent commercial contracts and US market expansion?